Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence-Reference-Cited by-同舟云学术

Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence

Published:2018-08-22 Issue:1 Volume:14 Page:
ISSN:1744-8603
Container-title:Globalization and Health
language:en
Short-container-title:Global Health

Author:

Wiktorowicz Mary^ORCID,Moscou Kathy,Lexchin Joel

Funder

Canadian Institutes of Health Research

Health Council of Canada

Canadian Patient Safety Institute

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy

Link

http://link.springer.com/content/pdf/10.1186/s12992-018-0402-5.pdf

Reference141 articles.

1. Carpenter D. Reputation and power: organizational image and pharmaceutical regulation at the FDA. Princeton: Princeton University Press; 2010.

2. Jasanoff S. Designs on nature: science and democracy in Europe and United States. Princeton, New Jersey: Princeton University Press; 2005.

3. Orenstein MA. In: Holzmann R, Orenstein M, Rutkowski M, editors. Mapping the diffusion of pension innovation, in Pension reform in Europe: Process and progress. Washington, DC: The World Bank; 2003. p. 171–84.

4. Coen D, Pegram T. Wanted: a third generation of global governance research. Governance. 2015;28(4):417–20.

5. Drezner DW. Globalization, harmonization, and competition: the different pathways to policy convergence. J Eur Publ Policy. 2005;12(5):841–59.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Regulation in Top Exporters of Pharmaceutical Products;Federalism;2023-10-07

2. Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries;Revista Panamericana de Salud Pública;2021

3. Regulation of veterinary point-of-care testing in the European Union, the United States of America and Japan;Revue Scientifique et Technique de l'OIE;2020-12-01

4. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018);Vaccine;2020-11

5. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States;Clinical Pharmacology & Therapeutics;2020-10-11